Key terms
About FULC
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FULC news
Mar 19
1:50am ET
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Mar 18
7:02am ET
Fulcrum Therapeutics appoints Horn as Chief Medical Officer
Mar 13
8:08am ET
RBC Capital starts Fulcrum Therapeutics at Outperform, sees two pipeline shots
Mar 13
7:28am ET
Fulcrum Therapeutics initiated with an Outperform at RBC Capital
Mar 08
10:46am ET
Biotech Alert: Searches spiking for these stocks today
Mar 05
6:14pm ET
Fulcrum Therapeutics CEO buys $492K in common stock
Mar 01
1:04am ET
Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability
Feb 28
7:47am ET
Oppenheimer Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)
Feb 28
7:32am ET
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)
Feb 28
7:28am ET
Fulcrum Therapeutics price target raised to $15 from $13 at Piper Sandler
Feb 28
6:17am ET
Fulcrum Therapeutics price target raised to $17 from $14 at H.C. Wainwright
Feb 27
5:14pm ET
Fulcrum Therapeutics files $350M mixed securities shelf
Feb 27
7:08am ET
Fulcrum Therapeutics expects cash to fund operations into 2026
Feb 27
7:08am ET
Fulcrum Therapeutics reports Q4 EPS (40c), consensus (43c)
Feb 09
8:29am ET
Stifel Nicolaus Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)
No recent press releases are available for FULC
FULC Financials
Key terms
Ad Feedback
FULC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FULC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range